Video

Taking a Closer Look at PCSK9 Part 3

Author(s):

As with any new class of medications there are many questions that will need to be answered by and for healthcare professionals.

As with any new class of medications there are many questions that will need to be answered by and for healthcare professionals. From costs to patient adherence, to overall usage PCSK9 promises to have long lasting effects on the medical community as a whole.

Jennifer Robinson, MD, MPH, from the University of Iowa addressed some of these questions during the American College of Cardiology Annual Scientific Sessions and Expo in San Diego.

Related Videos
Jörn Schattenberg, MD | Credit: Novo Nordisk
Jörn Schattenberg, MD | Credit: Novo Nordisk
The APAC Recap: Cardiomyopathy at CAPP Live 2024 with Greg Duck, PA-C | Image Credit: APAC
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
The APAC Recap: Peripheral Artery Disease at CAPP Live 2024 with Bob Ross, PA-C | Image Credit: APAC
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Malin Fromme, MD | Credit: RWTH Aachen
Pavel Strnad, MD | Credit: AASLD
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
© 2024 MJH Life Sciences

All rights reserved.